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Drugs are often used to suppress unwanted immune responses to antigenic stimuli. 
However, many clinically important  immune reactions are the sum of a  number of 
different immune factors working either synergistically or antagonistically. Attention 
has  been  given  to  those  situations  in  which  cell-mediated-immune  responses  are 
modulated by humoral blocking factors (1)  or by suppressor cells  (2-6).  There is a 
need  to  find  ways  of  selectively  affecting  undesirable  cell-mediated  or  humoral 
immunity  so that  the  balance  can  be shifted  toward  the  direction  of the  reaction 
desired in a particular situation. The drug cyclophosphamide (cy) seems to fulfill this 
goal.  It was first shown  to enhance  delayed type hypersensitivity reactions  in  mice 
and guinea pigs by damaging suppressor B cells (7-9)  and later to affect suppressor 
T  rather than B cells (10-12). Our own interest is in tumor immunology, and we have 
been attempting to find ways of using drugs to enhance immune responses to tumor 
associated antigens in the hope of achieving better immunotherapy of tumors as was 
suggested  elsewhere  (13,  14).  For  the  past  few  years  extensive  study  on  immune 
response  to  SV40-induced  transplantable  mKSA  cells  of BALB/c  mice  has  been 
performed in our laboratory. This tumor has been shown to possess tumor associated 
antigens  which  induce  specific transplantation  rejection  of the  tumor  (15-17).  Re- 
cently, we and others developed an in vitro SlCr release assay to measure the immune 
response against SV40-induced tumor associated antigens. The effector cells generated 
by antigen  immunization were shown to be T-cell dependent  (18,  19).  The present 
report is the first demonstration that treatment of mice with cy markedly augmented 
the specific cell-mediated cytotoxic reactivity against  tumor-associated  antigens  by 
damage of cy to T  cells which suppress in vivo the differentiation of antigen-specific 
cytotoxic T  cells. Thus treatment of mice with a single dose of cy converts their state 
of low to high responsiveness. 
Materials and Methods 
Mice.  Female CBFx (BALB/c ×  C57BL/6) F1 mice, aged 8-12 wk, were obtained from the 
National Institutes of Health breeding colony. 
Tumor Cell Lines.  SV40 transformed cells, C57SV of C57BL/6 mice were obtained from B. 
B. Knowles,  the Wistar Institute, Philadelphia, Pa. These cells are good targets in the in vitro 
SlCr release assay, but do not grow in vivo (18, 19). SV40 transformed cells, mKSA of BALB/ 
c mice grow in vivo but are poor targets in the in vitro cytotoxicity assay (16). Both cell lines 
were shown to possess tumor-associated transplantation antigens which can immunize specifi- 
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cally against the growth of mKSA cells  (17,  19). The MSB cell line was established from M- 
MuSV-induced  tumor  in  C57BL/6  mice  (20).  The  cells  were  passed  in  tissue  culture  by 
exposure to 0.25% trypsin. They are good target cells for in vitro 51Cr release  assay (20). 
Removal of B Cells and Phagocytic Cells.  The technique described by Julius et al. (21) was used. 
About 30% of the starting spleen cell population was recovered in the nonadherent fraction; of 
these  1-3%  (as compared to 40-45% in the unfraetionated population) were surface immuno- 
globulin-positive cells and 0.3% phagocytic cells (as compared to about 5% in the unfractionated 
population) as judged by latex particle ingestion. 
Removal of T Cells.  AKR anti-Thy 1.2 C3H antibody was kindly obtained from H. Holden, 
National Cancer Institute, Bethesda, Md. The preparation of this serum and the treatment of 
lymphoid  cells  were  performed  according to  the  technique  described  in  detail  (22).  This 
antiserum lysed more than 97% of C3H thymocytes and 35-40% of C3H spleen cells by trypan 
blue dye exclusion. The T-cell response of spleen cells to phytohemagglutinin was abolished 
after treatment, although the B-cell response to lipopolysaccharide was left intact. 
~a Cr Release Assay.  The assay was performed in the wells of flat bottom microplates. C57SV 
target cells  were trypsinized and  1  ×  104 cells  and  5 ~Ci  Na51CrO4 in 0.2 ml  RPMI-1640 
medium containing 5% fetal bovine serum were added to each well.  After 18 h at 37°C in a 
CO~ incubator,  the target cells were washed and  effector cells  were added  in 0.2 ml voi in 
various lymphocyte:target cell  ratios.  After 6 h  incubation at  37°C in a CO2 incubator,  the 
plates were centrifuged at 350 g for 5 min. 0.1 ml of the supernate was removed for counting. 
Results are calculated from the mean of triplicate samples and expressed as: 
Per cent-specific lysis  = 
cpm 51Cr released from cells in the presence of immune cells 
cpm 51Cr released from cells in the presence of normal cells ×  100. 
cpm SlCr released from cells in the presence of 1% SDS 
The 5~Cr released in the presence of normal cells was always either very close or identical to the 
release  in medium and ranged from 5 to 15%. Representative experiments are shown in Tables 
I-III. Each experiment was repeated three to four times with similar results. 
Hydrocortisone  Treatment.  2  mg of hydrocortisone acetate  (The  Upjohn  Co.,  Agricultural 
Prods. Mkt., Kalamazoo, Mich.) were injected i.p. into normal CBFI mice. The mice were used 
as lymphocyte donors 2 d later. 
Results 
The data of the first experiment  (Table I) demonstrate that after i.p. immunization 
of CBF1  mice  with  2  ×  107  C57SV  cells,  cell-mediated  cytotoxic  response  was 
generated in the spleens with peak activity at day 8, and this activity decreased to low 
levels by day 14. This finding is in accordance with earlier reports (18,  19). CBF1 mice 
treated  i.p. with cy 2 d  before C57SV cell immunization generated markedly higher 
levels of cytotoxic response which was still detected at day 20. Cy at a  concentration 
of 100 mg/kg had an optimal augmenting effect, whereas higher concentrations were 
less  effective.  These  results  implied  that  cy administered  in  vivo  before  antigenic 
immunization  can  augment  the  magnitude  and  kinetics  of cell-mediated  cytotoxic 
response  against  SV40  transformed  cells.  In Table  II  the  relationship  between  cy 
administration  before  or  after  antigen  immunization  and  the  cytotoxic  response 
generated  in vivo is observed.  CBFI mice were treated  i.p.  with  100 mg/kg of cy at 
various  times  before  or  after  i.p.  immunization  with  2  X  107  C57SV  cells.  The 
cytotoxicity assay was  performed  on day 8  after  antigen  inoculation.  The  optimal 
time for cy treatment  was 2 d  before in vivo antigen  immunization.  The effect of cy 
decreased with an increase in time interval between cy administration  before antigen 
inoculation and C57SV cell immunization.  Drug application simultaneously with, or 
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TAaL~  I 
The Effect of Treatment of CBF1 Mice with Cyclophosphamide on the In  Vivo Generation of Cell-Mediated 
Cytotoxic Response against SV40 Transformed Cells 
Dose of Cy* 
After C57SV cell immunization:[: 
2  4  6  8  10  14  20 
(  mg/  kg)  days 
0  5§  13  24  31  25  8  4 
25  5  12  26  33  21  10  5 
50  7  19  36  45  32  18  15 
100  8  23  48  62  53  46  34 
200  4  10  21  34  23  6  3 
* Cy was inoculated i.p. 2 d before C57SV cell immunization. 
:[: CBFx mice were inoculated  i.p. with 2  ×  107 C578V  cells 2  d  after cy treatment.  At  various  times 
thereafter spleens were  removed and  the cells were tested for cytotoxic activity  against  5aCr-labeled 
C57SV target cells. 
§ Percent eytotoxieity. 
TABLE II 
The Effect of Treatment of CBF1 Mice with Cyclophosphamide at  Various Intervals on the In  Vivo 
Generation of Cell-Mediated Cytotoxic Response against SV40 Transformed Cells 
Cy adminis- 
tration in re- 
lation to anti- 
gen immuni- 
zation:l: 
Cytotoxicity against: 
C57SV  MSB* 
100:1§  30:1  10:1  100:1  30:1  10:l 
days  Percent 
+6  5  4  4  4  4  3 
+4  20  13  6  4  6  4 
+2  24  10  5  6  4  5 
0  21  12  4  4  3  4 
-2  54  31  17  7  5  4 
-4  36  20  11  6  4  3 
-6  28  19  9  5  5  2 
* The conditions for the cytotoxicity assay are the same as for C57SV (see details in Table I.) 
:[: Cy at  100 mg/kg was administered i.p. at the time intervals listed in relation to i.p. inoculation of 2  X 
107 C57SV cells. The cytotoxicity assay was performed 8 d after antigen immunization. 
§ Effector:target cell ratio. 
administration 6 d after immunization resulted in suppression of cytotoxic response. 
These  results  implied  that  cy  administered  2  d  before  antigen  had  an  optimal 
augmenting effect on cell-mediated cytotoxic response, whereas cy administration 6 
d  after antigen had  a  suppressive  effect.  In  the  last  experiment  CBF1  mice were 
treated i.p. with  100 mg/kg of cy and 2 d  later were injected i.v. with various cell 
populations from normal CBF1  mice and then inoculated i.p. with 2  X  107 C57SV 
cells. The cytotoxicity assay was performed 8 d later. The results (Table III) indicate 
that transfer of T  cells abolished the cy-induced augmentation of cytotoxic response, 
implying that cy-sensitive T cells suppressed the in vivo generation of specific cytotoxic 
T  lymphocytes against SV40 transformed cells. 
Discussion 
The  new  aspects  of the  present  study  are  that  pretreatment  of mice  with  cyclo- 
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TABLE  III 
The Effect of Transfer  of Different Cell Populations  to Cyclophosphamide-Treated  Mice on the Ability to 
Generate In  Vivo Cell-Mediated Cytotoxicity  against  SV40  Transformed  Cells 
Cells transferred (60  X  10  a) 
Cytotoxicity 
100:1"  30:1  10:1 
None 
Unfractionated spleen 
Nylon wool column spleen 
Anti-Thy 1.2 serum and complement-treated  spleen 
Complement-treated spleen 
Cortisone-resistant thymus 
Anti-Thy 1.2 serum and complement-treated  bone marrow 
Percent 
50  38  23 
23  12  4 
2O  10  6 
47  35  21 
18  11  7 
23  14  8 
52  36  19 
*Effector:target cell ratio, 
in  marked  augmentation of their  ability to  generate  in  vivo antigen-specific cell- 
mediated cytotoxic response. Because the in vitro cytotoxic reactivities observed in 
syngeneic tumor systems are often weak or even undetectable, cy treatment may be 
used to convert such state of low to high responsiveness. Moreover, by such manipu- 
lation, it is hoped to achieve more effective ways for immunotherapy of tumors (13, 
14). We are currently studying the possible augmenting effect ofcy on in vivo rejection 
of lethal  syngeneie tumors.  The  conversion  to  high  responsiveness  by  cy can  be 
reverted to a state of low responsiveness by reconstituting the cy-treated animals with 
normal  T  cells,  suggesting that  in  vivo  cy-sensitive T  cells  suppress  the  in  vivo 
generation  of T  cells  cytotoxic  against  SV  40  transformed  cells.  An  interesting 
observation  in  the  present  study is  that  cy  treatment  of mice  6  d  after  antigen 
immunization resulted in suppression of cell-mediated cytotoxic response. This phe- 
nomenon which is in accord with the one reported in an allogeneic system (23) is now 
under study. Our results of augmentation of cell-mediated immunity against tumor- 
associated antigens are similar to those demonstrating that cy enhanced delayed type 
hypersensitivity reactions  by  elimination  of suppressor  B  cells  (7-9)  and  recently 
augmented cell-mediated cytotoxic response against  alloantigens by elimination of 
suppressor T  cells (10). These reports together with the data presented here favor the 
concept  that T-cell-immune responsiveness in vivo against  a  variety of antigens is 
under the control of cy-sensitive suppressor T  cells. 
Summary 
When  cyclophosphamide was  administered  to  mice  before  immunization with 
syngeneic  SV40  transformed  cells,  the  specific  immune  response  elicited,  as  was 
measured by in vitro 51Cr release assay was stronger and lasted longer when compared 
to the response generated in noncyclophosphamide-treated mice. The augmentation 
effect of the drug was dependent on cyclophosphamide concentration being optimal 
at  100  mg/kg  and  on  the  time  of  drug  administration  in  relation  to  antigen 
immunization being optimal at 2 d before antigen administration. Transfer of T  cells 
from normal syngeneic mice to drug-treated animals abolished the cyclophosphamide- 
induced augmentation of immune response. These results implied that cyclophospha- 
mide sensitive T  cells suppressed  the in vivo generation of specific effector T  cells 
against SV40-induced tumor-associated antigens. 778  MOSHE  GLASER  BRIEF DEFINITIVE REPORT 
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